mardi 27 novembre 2018

Onco Actu du 27 novembre 2018

1. Biologie

Science Snaps: spotting lung cancers’ ‘crime hotspots’ [Cancer Research UK]

1.4 Biologie - Technos

An outsider claimed to make genome-editing history — and the world snapped to attention [STAT]

Chinese university to investigate after academic claims to have edited twins’ genes [Reuters]

4.2 Dép., diag. & prono. - Génome

Gene test predicts likelihood of stomach or oesophageal cancer relapse [Institute of Cancer Research]

5.10 Traitements - Essais

Tailored Radiation to Treat Brain Metastases Reduces Impact on Cognitive Function [NCI]

5.12.3 Immunothérapies-combinaisons

CheckMate-451: Bristol-Myers’ Opdivo — plus Yervoy — fails PhIII combo lung cancer study, the latest in a series of setbacks [EndPoints]

Bristol-Myers Squibb says cancer drug combination fails late-stage trial [Reuters]

Bristol-Myers Squibb Announces CheckMate -451 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo Plus Yervoy Vs. Placebo as A Maintenance Therapy in Patients with Extensive-Stage Small Cell Lung Cancer After Completion of First-Line Chemotherapy [BMS]

5.12.8 Immunothérapies - Economie

Novartis CEO says four factors can help with pricing and payment of lifesaving cell and gene therapies [CNBC]

5.2 Pharma

AbbVie, Roche aim to face down Pfizer with Venclexta’s move into AML arena [FiercePharma]

On a roll with FDA approvals, Pfizer doubles down in AML with Daurismo nod [FiercePharma]

5.3.4 Traitements - AMM (FDA, EMA,...)

Loxo, Bayer drug for cancers driven by rare mutation gets U.S. nod [Reuters]

Shattering an old record, FDA quickly OKs pioneering, site-agnostic cancer drug larotrectinib from Loxo and Bayer [EndPoints]

Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues [Xconomy]

FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2) [Loxo Oncology]

Loxo And Bayer's Amazing Drug Has An Expensive Price [Forbes]

FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor [FDA]

FDA approves ‘precision medicine’ drug for different cancers with same mutation [Washington Post]

Kyowa Kirin Announces POTELIGEO® Receives Marketing Authorisation in Europe for the Treatment of Mycosis Fungoides and Sézary Syndrome [Kyowa Kirin]

5.8 ASH

ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More [Xconomy]

5.8.2 ASH - Pharma

AstraZeneca presents clinical research advances for blood cancer patients at 2018 American Society of Hematology Annual Meeting [AstraZeneca]

5.8.4 ASH - CAR T

Fred Hutch at ASH: Press briefing on a combination CAR T-cell therapy, other CAR T insights, CRISPR for blood disorders, and more [Fred Hutch]

6.1 Observation

Cancer early detection rates stall as patients 'too embarrassed' to trouble their GP with symptoms [The Telegraph]

Cancer care: England still lagging behind the best [BBC News]

6.2 Implants mammaires

Australian database seeks to identify breast implant risks [The Guardian]

Breast implants study reveals serious safety concerns [The Guardian]

Rare cancer linked to breast implant used by millions of women [The Guardian]

6.6 Publications

European funders detail their open-access plan [Science]

Do You Have Concerns about Plan S? Then You Must be an Irresponsible, Privileged, Conspiratorial Hypocrite [The Scholarly Kitchen]

6.7.3 DMP

Patient-Led Data Sharing — A New Paradigm for Electronic Health Data [NEJM Catalyst]

6.9 Controverses

Statement from FDA Commissioner Scott Gottlieb, M.D. and Jeff Shuren, M.D., Director of the Center for Devices and Radiological Health, on transformative new steps to modernize FDA’s 510(k) program to advance the review of the safety and effectiveness of medical devices [FDA]

FDA plans overhaul of decades-old medical device system [STAT]

RCS statement on medical device regulation [Royal College of Surgeons]